Amphastar PharmaceuticalsAMPH -0.15%83 Return-on-Tangible-Asset is 2.39% as of Mar. 2026, which is 75% below its 10-year median of 9.60. GuruFocus rates AMPH with a GF Scoreâ„¢ of 83/100 and a GF Valueâ„¢ of $48.84 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 69.25% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amphastar Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was $25.7 Mil. Amphastar Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was $1,075.9 Mil. Therefore, Amphastar Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 2.39%.
The historical rank and industry rank for Amphastar Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
AMPH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.31 Med: 9.6 Max: 17.15
Current: 7.44
During the past 13 years, Amphastar Pharmaceuticals's highest Return-on-Tangible-Asset was 17.15%. The lowest was -1.31%. And the median was 9.60%.
AMPH's Return-on-Tangible-Asset is ranked better than 69.25% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs AMPH: 7.44
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Amphastar Pharmaceuticals Return-on-Tangible-Asset Related Terms
Amphastar Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Amphastar Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.39% mean?
Amphastar Pharmaceuticals (AMPH) has a Return-on-Tangible-Asset of 2.39% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amphastar Pharmaceuticals and its competitors. This is 75% below median its historical median of 9.60. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #309 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Amphastar Pharmaceuticals' Return-on-Tangible-Asset too high?
Amphastar Pharmaceuticals' current Return-on-Tangible-Asset of 2.39% is 75% below median its 10-year median of 9.60. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Amphastar Pharmaceuticals' value of 2.39% is 24.4% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #309 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Scoreâ„¢ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Return-on-Tangible-Asset compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #309 out of 1005 companies for Return-on-Tangible-Asset. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Amphastar Pharmaceuticals' value of 2.39% is 24.4% below this benchmark. While the company's 10-year median is 9.60 vs. the industry median of 3.16, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current Return-on-Tangible-Asset of 2.39% is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current Return-on-Tangible-Asset is 2.39%, which is 75% below median its own 10-year median of 9.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.84, compared to a current price of $19.61 — trading 59.8% below its estimated fair value. The current Return-on-Tangible-Asset is 2.39%, which is 75% below median its 10-year median of 9.60 and 24.4% below the Drug Manufacturers industry median of 3.16. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Return-on-Tangible-Asset is 2.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $19.61 is trading 59.8% below its estimated GF Value™ of $48.84.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
Return-on-Tangible-Asset: 2.39% (75% below median its 10-year median of 9.60)
GF Value™: $48.84 vs. price of $19.61 (59.8% below fair value)
Industry Position: 24.4% below the Drug Manufacturers median (#309 of 1005)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
